Toxicology

A startup made it all the way through partner meetings, technical validation, and market analysis. Then diligence started. Two weeks later, the deal slowed. Four weeks later, the valuation dropped. Six weeks later, the lead investor walked away.

Hook:An investor once passed on a startup with strong technology, a clear market, and early traction. Their reason? “The regulatory risk is unclear.” Not high. Not […]

startup had everything investors usually want—strong prototype, clear market, experienced team. Then one question changed the entire conversation: “What’s your clinical risk?” The room shifted. The valuation dropped. The timeline stretched. The deal slowed.

A founder once celebrated getting FDA feedback: “Clinical data will be required.” It sounded like progress. Six months later, they were back in the market raising emergency capital. Same device. Same team. But now their burn rate had doubled—and their valuation had dropped.